RT Journal Article
T1 Changes in the immune phenotype and gene expression profile driven by a novel tuberculosis nanovaccine: short and long-term post-immunization
A1 Martinez Perez, Amparo
A1 Igea Fernandez, Ana
A1 Estévez Martínez, Olivia
A1 Ferreira, Catarina M.
A1 Torrado, Egídio
A1 Castro, António Gil
A1 Fernández, Carmen
A1 Spetz, Anna Lena
A1 Adam, Lucille
A1 López González, Moisés
A1 Singh, Mahavir
A1 Reljic, Rajko
A1 González Fernández, Maria Africa
K1 2412 Inmunología
K1 3205.08 Enfermedades Pulmonares
AB Deciphering protection mechanisms against Mycobacterium  tuberculosis (Mtb) remains a critical challenge for the development of  new vaccines and therapies. We analyze the phenotypic and  transcriptomic profile in lung of a novel tuberculosis (TB) nanoparticle-based boosting mucosal vaccine Nano-FP1, which combined to BCG priming conferred enhanced protection in mice challenged with low-dose Mtb. We analyzed the vaccine profile and efficacy at short (2 weeks), medium (7 weeks) and long term (11 weeks) post-vaccination, and compared it to ineffective Nano-FP2 vaccine. We observed several changes in the mouse lung environment by both nanovaccines, which are lost shortly after boosting. Additional boosting at long-term (14 weeks) recovered partially cell populations and transcriptomic profile, but not enough to enhance protection to infection. An increase in both total and resident memory CD4 and CD8 T cells, but no pro-inflammatory cytokine levels, were correlated with better protection. A unique gene expression pattern with differentially expressed genes revealed potential pathways associated to the immune defense against Mtb. Our findings provide an insight into the critical immune responses that need to be considered when assessing the effectiveness of a novel TB vaccine.
PB Frontiers in Immunology
SN 16643224
YR 2021
FD 2021-01-28
LK http://hdl.handle.net/11093/2509
UL http://hdl.handle.net/11093/2509
LA eng
NO Frontiers in Immunology, 11, 624567 (2021)
NO Xunta de Galicia | Ref. ED431C 2016/041
DS Investigo
RD 10-dic-2024